

1 **Title:** A new Omicron lineage with Spike Y451H mutation that dominated a new COVID-19
2 wave in Kilifi, Coastal Kenya: March-May 2023

3

4 **Authors**

5 Mike J Mwangi^{1*}, Arnold W Lambisia^{1*}, John Mwita Morobe^{1*}, Nickson Murunga^{1*}, Edidah
6 Moraa¹, Leonard Ndwiga¹, Robinson Cheruiyot¹, Martin Mutunga¹, Laura M Guzman-
7 Rincon², Charles Sande¹, Joseph Mwangangi¹, Philip Bejon¹, Lynette Isabella Ochola-Oyier¹,
8 D James Nokes^{1,4}, Charles N Agoti^{1,5}, Joyce Nyiro¹, George Githinji^{1,3§}

9

10 **Affiliations**

11 ¹ KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

12 ² Mathematics Institute, University of Warwick, CV4 7AL, UK

13 ³ Department of Biochemistry and Biotechnology, Pwani University, Kilifi, Kenya

14 ⁴ School of Life Sciences and Zeeman Institute for Systems Biology and Infectious Disease

15 Epidemiology Research (SBIDER), University of Warwick, Coventry, UK

16 ⁵ School of Public Health, Pwani University, Kilifi, Kenya

17

18 * Authors contributed equally to this article

19 § corresponding author ggithinji@kemri-wellcome.org

20

21 **Word Count**

22 Abstract : 50

23 Main text : 788

24

25 **Running Title**

26 New FY.4 Omicron lineage in Kilifi, Kenya

27

28 **Key Words**

29 FY.4, SARS-CoV-2, Omicron, Kilifi, Kenya

30

31 **Abstract**

32 We report a newly emerged SARS-CoV-2 Omicron lineage, named FY.4, that has two unique
33 mutations; spike:Y451H and ORF3a:P42L. FY.4 emergence has coincided with increased
34 SARS-CoV-2 cases in coastal Kenya, April-May 2023. We demonstrate the value of
35 continued SARS-CoV-2 genomic surveillance in the post-acute pandemic era in
36 understanding new COVID-19 outbreaks.

37

38 **Main Text**

39 To date over 340,000 test-confirmed COVID-19 cases and 5,688 COVID-19-related
40 deaths have been reported in Kenya[1]. Sero-surveillance reports indicated a high
41 seropositivity in rural and urban populations despite low vaccine uptake (27.9% of the adult
42 population vaccinated with at least one dose)[2]. Specifically, by August 2022, 69%-81% of
43 rural (Kilifi and Siaya) and 89%-95% of urban (Nairobi and Kisumu) adult population in
44 Kenya had anti-Spike glycoprotein IgG antibodies (not published).

45 Genomic surveillance has been critical in informing origins of new waves, evolution,
46 and geographical spread patterns of SARS-CoV-2. By June 2023, seven distinct waves of
47 SARS-COV-2 infections were observed in Kenya[1][3]. The last three were dominated by
48 Omicron sub-variants: BA.1-like, BA.5-like and BQ-like, respectively. These sub-variants
49 were associated with increase in SARS-CoV-2 cases due to possession of mutations that
50 conferred pre-existing immunity escape and transmission advantage[4].

51 In coastal Kenya, the KEMRI-Wellcome Trust Research Programme (KWTRP) has
52 been conducting SARS-CoV-2 genomic surveillance across five health facilities (HF) within
53 the Kilifi Health and Demographic Surveillance System (KHDSS)[5]. Samples are collected
54 weekly from individuals of all ages presenting with acute respiratory illness (ARI) for
55 screening. SARS-CoV-2 testing and sequencing is performed on: (i) samples collected from
56 persons seeking medical attention from selected HF within the KHDSS and (ii) positive
57 SARS-CoV-2 samples from collaborating public and private HF across Kenya.

58 Beginning late March, SARS-CoV-2 positivity rate in the HF increased from a
59 background level of 1.2% in the week commencing 27th March, and peaked at 42.9%, in the
60 week commencing 24th April (Figure, panel A). However, the positivity rate dropped in the
61 first week of May to 23.5% and ranged between 5.0%-7.7% over the next three weeks.
62 Between January and May 2023, 76 samples were sequenced and assigned into three
63 lineages; BQ.1.1(n=1), BA.1.1(n=2) and FY.4(n=73). The increase in the positivity rate
64 starting late March coincided with detection of a new Omicron lineage namely, FY.4 (Figure,
65 panel B). In Kenya, the FY.4 lineage was first observed in Lamu County(n=4) on the 10th
66 March 2023 (Figure panel A). By 27th May 2023, this new FY.4 lineage was further detected
67 in four additional counties including the coastal counties of Kwale(n=2), and Mombasa(n=2),
68 and central counties of Kiambu(n=5) and Nairobi(n=4). In Kilifi, FY.4 variants were first
69 detected from samples collected on 27th March 2023 and by April and May they became the
70 predominant lineage representing 97% of all the detected lineages. Kenya is the first country
71 to report the circulation of FY.4 lineage and has so far (based on GISAID data accessed on
72 30th June 2023) been detected in eleven other countries; Austria, Germany, Italy, Sweden,
73 Canada, France, China, Australia, Spain, United Kingdom and United States[6].

74 Participants who had the FY.4 variant presented to the KHDSS HF mainly with cough
75 (98%), fever (78%) and nasal discharge (74%) while 7% presented with difficulties in

76 breathing (Table). Only 13 (16%) participants had received at least one dose of the
77 AstraZeneca vaccine. However, a sero-surveillance study (February – June 2022) show that
78 67% of the unvaccinated KHDSS residents have anti-SARS-CoV-2 IgG antibodies showing
79 that a high proportion of this population may have naturally acquired immunity from
80 previous exposure[7].

81 Relative to other Omicron lineages, the FY.4 has two additional amino acid mutations;
82 in the spike(Y451H) and ORF3a(P42L) genes. The potential phenotypic impact of the Y451H
83 change remains unknown. Previous studies have shown that spike amino acid change in the
84 receptor binding domain (RBD) near the Y451H, such as L452R increases virus infectivity
85 and fusogenicity by enhancing spike stability and cleavage[8]. However, mutations within the
86 ORF3a CD8⁺ T cell epitopes have been reported to cause complete loss of recognition in the
87 ancestral lineages and Alpha VOC[9].

88 We applied a Bayesian hierarchical model[10] to estimate the growth rate of the FY.4-
89 like lineage in Kenya. These estimates serve as warning system for lineages showing
90 consistent increase in frequency for at least two consecutive weeks in Kenya and/or other
91 countries. Growth rate estimates on Kenyan data was compared to data from Germany and
92 USA, as these were the only countries with reported FY.4 cases in at least two consecutive
93 weeks as of the last weeks of May (Figure, panel C). The model has warned of a high level of
94 concern in Kenya as from week of March 26 towards May, suggesting continued increase in
95 cases attributed to the FY.4 lineage.

96 In summary, surveillance of SARS-CoV-2 in Kenya has detected the emergence of a
97 new Omicron lineage with unique spike and ORF3a gene mutations. Detection of FY.4
98 lineage coincided with increase in SARS-CoV-2 cases in Kilifi and has also been detected in
99 other parts of the country. Growth estimates suggests potential for continued increase in

100 geographical spread of FY.4. Further analysis on the immunological impacts of the observed
101 mutations and any transmission advantage arising are ongoing.

102

103 **Acknowledgement**

104 We thank the laboratories, hospitals and organisations that shared specimens for
105 sequencing at KWTRP and the submitting laboratories where genetic sequence data were
106 generated and shared via the GISAID Initiative, on which this research is based. Submitting
107 and the Originating laboratories of the GISAID data used in this study are listed in the
108 [gisaid_supplemental_table_epi_set_230627qs.pdf](#)

109 **Funding**

110 This work was supported by (i) New Variant Assessment Programme (NVAP), The
111 New Variant Assessment Platform (NVAP) is a UK Health Security Agency programme
112 funded by the UK Department of Health and Social Care (DHSC) as a global initiative to
113 strengthen genomic surveillance for pandemic preparedness and response to emerging and
114 priority infectious diseases, National Institute for Health and Care Research (NIHR) (project
115 references 17/63/82 and 16/136/33) using UK Aid from the UK Government to support
116 global health research, The UK Foreign, Commonwealth and Development Office (FCDO)
117 and (ii) The Wellcome, UK (grant# 220985/Z/20/Z and 226002/A/22/Z). The views
118 expressed in this publication are those of the author(s) and not necessarily those of NIHR, the
119 Department of Health and Social Care, or the Foreign Commonwealth and Development
120 Office, the Africa-CDC, WHO-Afro, ASLM.

121 **Data Availability**

122 Genome sequences generated in this study are available on GISAID. Generated
123 genomes are listed in the [gisaid_supplemental_table_epi_set_230627zw.pdf](#). The, the dataset

124 and analysis scripts used are available in Havard Dataverse at
125 <https://doi.org/10.7910/DVN/ZMGR5P>.

126

127 **Conflict of Interest**

128 Authors declare no conflict of interest.

129 **Ethical Statement**

130 The whole genome sequencing study protocol was reviewed and approved by the
131 Scientific and Ethics Review Committee (SERU) residing at the Kenya Medical Research
132 Institute (KEMRI) headquarters in Nairobi (SERU # 4035).

References:

- [1] E. Mathieu *et al.*, “Coronavirus Pandemic (COVID-19),” *Our World Data*, 2020.
- [2] WHO - World Health Organization, “Africa COVID-19 Vaccination dashboard,” 2023. .
- [3] G. Githinji *et al.*, “The genomic epidemiology of SARS-CoV-2 variants of concern in Kenya,” *medRxiv*, 2022, doi: <https://doi.org/10.1101/2022.10.26.22281446>.
- [4] Q. He *et al.*, “An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB,” *Cell Reports Med.*, vol. 4, no. 4, p. 100991, Apr. 2023, doi: [10.1016/j.xcrm.2023.100991](https://doi.org/10.1016/j.xcrm.2023.100991).
- [5] J. A. G. Scott *et al.*, “Profile: The Kilifi Health and Demographic Surveillance System (KHDSS),” *Int. J. Epidemiol.*, vol. 41, no. 3, pp. 650–657, Jun. 2012, doi: [10.1093/ije/dys062](https://doi.org/10.1093/ije/dys062).
- [6] Y. Shu and J. McCauley, “GISAID: Global initiative on sharing all influenza data – from vision to reality,” *Eurosurveillance*, vol. 22, no. 13, pp. 2–4, Mar. 2017, doi: [10.2807/1560-7917.ES.2017.22.13.30494](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494).
- [7] E. W. Kagucia *et al.*, “SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022,” *medRxiv*, 2022, doi: [10.1101/2022.10.10.22280824](https://doi.org/10.1101/2022.10.10.22280824).
- [8] C. Motozono *et al.*, “SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity,” *Cell Host Microbe*, vol. 29, no. 7, pp. 1124-1136.e11, Jul. 2021, doi: [10.1016/j.chom.2021.06.006](https://doi.org/10.1016/j.chom.2021.06.006).
- [9] T. I. de Silva *et al.*, “The impact of viral mutations on recognition by SARS-CoV-2 specific T cells,” *iScience*, vol. 24, no. 11, p. 103353, Nov. 2021, doi: [10.1016/j.isci.2021.103353](https://doi.org/10.1016/j.isci.2021.103353).
- [10] L. M. Guzmán-Rincón, E. M. Hill, L. Dyson, M. J. Tildesley, and M. J. Keeling,

“Bayesian estimation of real-time epidemic growth rates using Gaussian processes: local dynamics of SARS-CoV-2 in England,” *J. R. Stat. Soc. Ser. C Appl. Stat.*, Jun. 2023, doi: 10.1093/jrsssc/qlad056.

Table: Distribution of observed clinical symptoms among the FY.4 cases observed in Kilifi Health Demographic Surveillance System between January – May 2023


Symptoms	Omicron FY.4 (n=73)
Fever	
Yes	57 (78.1%)
No	16 (21.9%)
Cough	
Yes	72 (98.6%)
No	1 (1.4%)
Nasal discharge	
Yes	54 (74.0%)
No	19 (26.0%)
Difficulty in breathing	
Yes	5 (6.8%)
No	68 (93.2%)
Sore throat	
Yes	28 (38.4%)
No	45 (61.6%)
Body malaise	
Yes	25 (34.2%)
No	48 (65.8%)
Conscious level	
Alert	73 (100.0%)
COVID-19 Vaccination status	
Yes	12 (16.4%)
No	60 (82.2%)
No data	1 (1.4%)
COVID19 vaccine doses	
1	3 (4.1%)
2	7 (9.6%)
No data	63 (86.3%)

Figure legend


Figure: Panel A – Weekly number of collected samples (horizontal dotted line) and positive

SARS-CoV-2 cases (bars) in health facilities within the Kilifi Health Demographic Surveillance System (KHDSS) between January – May 2023. Vertical dotted lines represent time points when FY.4 lineage was first detected in Kenya and in Kilifi. Panel B – Weekly distribution of SARS-CoV-2 lineages observed in the KHDSS between January – May 2023. Panel C – Growth rate estimates of the FY.4 variant in Kenya relative to USA and Germany.

A



B



C

